Taking Gene-Silencing to the DNA Level

Oncogenuity is developing novel oligonucleotides for the treatment of genetically driven diseases, including cancers and coronaviruses by targeting gene-silencing at the DNA level.

What Sets Us Apart

We Target the Root of Genetic Diseases

Our pipeline of targeted therapeutics against genetic mutations is a result of combining gene sequence data with rigorous statistical, mechanical and molecular modeling.

View Pipeline

Targeting Mutations Historically Considered “Un-Druggable”


Our proprietary platform produces oligomers, now known as “ONCOlogues,” that are capable of binding gene sequences 1,000 times more effectively than complementary native DNA.

Explore Our Technology